Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
| ▸ | AOC1 | P19801 | 1/20 | 0.32 |
| ▸ | SAT1 | P21673 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469731 | 0.89 | TMPRSS2 (0.46) | MEN1NPC1RAB9AKMT2ATMPRSS2 | |
| SCHEMBL17469632 | 0.83 | SLC16A3 (0.40) | MEN1NPC1RAB9AKMT2ATMPRSS2 | |
| SCHEMBL21153028 | 0.74 | NPC1 (0.40) | ACACBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL17469629 | 0.68 | SLC16A3 (0.43) | ACACBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL19006327 | 0.68 | ALDH1A1 (0.38) | MEN1NPC1RAB9AKMT2AAPP | |
| SCHEMBL17469670 | 0.68 | FURIN (0.52) | MEN1NPC1RAB9AKMT2ATMPRSS2 | |
| SCHEMBL1186050 | 0.63 | NPC1 (0.59) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL22670488 | 0.62 | TMPRSS2 (0.79) | MEN1NPC1RAB9AKMT2ATMPRSS2 | |
| SCHEMBL14169148 | 0.62 | TMPRSS2 (0.79) | MEN1NPC1RAB9AKMT2ATMPRSS2 | |
| SCHEMBL22062151 | 0.62 | NPC1 (0.71) | MEN1NPC1RAB9AKMT2ATMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | ACACB 1269/4885MEN1 1462/4885NPC1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.